Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease

Christian Schulte; Temo Barwari; Abhishek Joshi; Tanja Zeller; Manuel Mayr

doi:10.1016/j.molmed.2020.02.001

Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease

Standard

Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. / Schulte, Christian; Barwari, Temo; Joshi, Abhishek; Zeller, Tanja; Mayr, Manuel.

In: TRENDS MOL MED, Vol. 26, No. 6, 06.2020, p. 583-596.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Schulte, C, Barwari, T, Joshi, A, Zeller, T & Mayr, M 2020, 'Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease', TRENDS MOL MED, vol. 26, no. 6, pp. 583-596. https://doi.org/10.1016/j.molmed.2020.02.001

APA

Schulte, C., Barwari, T., Joshi, A., Zeller, T., & Mayr, M. (2020). Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. TRENDS MOL MED, 26(6), 583-596. https://doi.org/10.1016/j.molmed.2020.02.001

Vancouver

Schulte C, Barwari T, Joshi A, Zeller T, Mayr M. Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. TRENDS MOL MED. 2020 Jun;26(6):583-596. https://doi.org/10.1016/j.molmed.2020.02.001

Bibtex

@article{bc7c0d0dbd3146b39ee6ee664f1c4a37,

title = "Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease",

abstract = "The development of more sensitive protein biomarker assays results in continuous improvements in detectability, extending the range of clinical applications to the detection of subclinical cardiovascular disease (CVD). However, these efforts have not yet led to improvements in risk assessment compared with existing risk scores. Noncoding RNAs (ncRNAs) have been assessed as biomarkers, and miRNAs have attracted most attention. More recently, other ncRNA classes have been identified, including long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs). Here, we compare emerging ncRNA biomarkers in the cardiovascular field with protein biomarkers for their potential in clinical application, focusing on myocardial injury.",

keywords = "Animals, Biomarkers/metabolism, Cardiovascular Diseases/genetics, Humans, MicroRNAs/genetics, Proteins/genetics, RNA, Circular/genetics, RNA, Long Noncoding/genetics",

author = "Christian Schulte and Temo Barwari and Abhishek Joshi and Tanja Zeller and Manuel Mayr",

year = "2020",

month = jun,

doi = "10.1016/j.molmed.2020.02.001",

language = "English",

volume = "26",

pages = "583--596",

journal = "TRENDS MOL MED",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "6",

}

RIS

TY - JOUR

T1 - Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease

AU - Schulte, Christian

AU - Barwari, Temo

AU - Joshi, Abhishek

AU - Zeller, Tanja

AU - Mayr, Manuel

PY - 2020/6

Y1 - 2020/6

N2 - The development of more sensitive protein biomarker assays results in continuous improvements in detectability, extending the range of clinical applications to the detection of subclinical cardiovascular disease (CVD). However, these efforts have not yet led to improvements in risk assessment compared with existing risk scores. Noncoding RNAs (ncRNAs) have been assessed as biomarkers, and miRNAs have attracted most attention. More recently, other ncRNA classes have been identified, including long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs). Here, we compare emerging ncRNA biomarkers in the cardiovascular field with protein biomarkers for their potential in clinical application, focusing on myocardial injury.

AB - The development of more sensitive protein biomarker assays results in continuous improvements in detectability, extending the range of clinical applications to the detection of subclinical cardiovascular disease (CVD). However, these efforts have not yet led to improvements in risk assessment compared with existing risk scores. Noncoding RNAs (ncRNAs) have been assessed as biomarkers, and miRNAs have attracted most attention. More recently, other ncRNA classes have been identified, including long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs). Here, we compare emerging ncRNA biomarkers in the cardiovascular field with protein biomarkers for their potential in clinical application, focusing on myocardial injury.

KW - Animals

KW - Biomarkers/metabolism

KW - Cardiovascular Diseases/genetics

KW - Humans

KW - MicroRNAs/genetics

KW - Proteins/genetics

KW - RNA, Circular/genetics

KW - RNA, Long Noncoding/genetics

U2 - 10.1016/j.molmed.2020.02.001

DO - 10.1016/j.molmed.2020.02.001

M3 - SCORING: Review article

C2 - 32470385

VL - 26

SP - 583

EP - 596

JO - TRENDS MOL MED

JF - TRENDS MOL MED

SN - 1471-4914

IS - 6

ER -